PredicineWES+™

About Predicine

Predicine is a private, commercial-stage diagnostics company advancing a next-generation liquid biopsy platform. Its core technology, GeneRADAR, uniquely profiles both DNA and RNA from blood and urine, aiming for more accurate and holistic cancer biomarker detection. The company provides a suite of assay services (e.g., PredicineCARE™, PredicineBEACON™) and partners with biopharma firms to support global clinical trials from its CLIA/CAP labs in the US and China. Predicine is positioned in the high-growth liquid biopsy market, competing on its dual DNA/RNA analysis and urine-based capabilities.

Therapeutic Areas